Switzerland· 65839006
Nordimet 20.0 mg/0.8 ml, Injektionslösung in einer Fertigspritze
A methotrexate product, registered in Switzerland by Nordic Pharma GmbH and dispensed under Swissmedic category A. The same ATC class is registered in 15 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Methotrexate is registered in 15 of 19 countries.
Countries holding a registration under ATC L04AX03 (methotrexate), each read from that country’s own register.
- This record: Switzerland
- 9 of them publish a price we can compare per daily dose
Methotrexate · ATC L04AX03
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of methotrexate costs, country by country.
Normalised to the WHO defined daily dose (2.5 mg), the median price runs from $0.16 in United States to $5.98 in Switzerland — a ×38 gap.
- Switzerland: $5.98 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Methotrexate · price per daily dose (2.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$5.98
- IT Italy$0.20
- US United States$0.16 (acquisition cost)
The record
At a glance
- Manufacturer
- Nordic Pharma GmbH
- Country
- Switzerland (CH)
- ATC code
- L04AX03
- ATC class
- Methotrexate
- Defined daily dose
- 2.5 mg, O
- Swissmedic category
- A
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
929 interactions on record for methotrexate.
Graded by severity as the source publishes them — 107 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Methotrexate · interactions on record
929 records
- 107 severe
- 466 moderate
- 17 minor
- 309 info
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
30 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AX03
Methotrexate, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cceed867-e439-4b71-8737-67063993b0cc GET /v1/drugs/cceed867-e439-4b71-8737-67063993b0cc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about methotrexate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.